Why has ASP Isotopes Inc. stock dropped over 45% despite strong fundamentals like 5407.52% revenue growth and $23.85M net income?

The news states that ASP Isotopes Inc. (ASPI) is a development-stage advanced materials company focused on producing isotopes for healthcare, technology, and nuclear fuels; although it shows strong fundamentals—including average revenue growth of 5407.52% and total net income of $23.85M—the stock has dropped over 45% in the last month, and its valuation is considered overvalued with a P/E of -1.89, which may reflect market skepticism toward profitability sustainability or earnings quality given the negative P/E ratio in a development-stage context.

What is the current analyst consensus and price target for ASP Isotopes Inc., and what upside does it imply?

Analysts currently rate ASP Isotopes Inc. as a 'Buy' with a target price of $13.00, representing over 205% upside potential, according to the news—despite the stock’s recent 45% decline and its overvalued P/E of -1.89, suggesting analysts expect significant near-term re-rating based on fundamentals or upcoming catalysts not detailed in the body.

ASP Isotopes Inc. Stock Drops Despite Strong Fundamentals

Jul 25, 2026

ASP Isotopes Inc., an advanced materials firm producing isotopes for healthcare and nuclear fuels, saw shares fall over 45% despite significant revenue growth and a 'Buy' analyst rating.

TradingKey

2026-03-31

ASP Isotopes Partners with University of Bristol, Survives Class-Action Lawsuit

2026-04-11

ASP Isotopes Inc Targets Initial Commercial Shipments for Key Isotopes by 2026-2027

2026-04-12

ASP Isotopes Revenue Surge Tests Bullish Growth Narratives Against Deepening Losses

2026-04-13

ASP Isotopes Reports Q4 Revenue Surge Amid Widening Losses

2026-04-13

$333M Cash Backs ASP Isotopes' 2026 Push for First Sales